Pulmonary Hypertension
Clinicians agree on individualized dosing, titration of selexipag in PAH
Health care professionals treating patients with pulmonary arterial hypertension recommend individualized dosing and titration of oral selexipag, according to a poster presented at the International Pulmonary Hypertension Conference.
FDA grants orphan drug designation to PAH treatment
The FDA granted orphan drug designation to ZMA001 as a treatment for patients with pulmonary arterial hypertension, according to a press release from Zymedi.
Electrocardiogram-based AI algorithm identifies pulmonary hypertension before diagnosis
An AI algorithm had high discriminative ability in identifying pulmonary hypertension-likely patients from control patients at and before diagnosis using electrocardiogram data, according to study results.
Longer lifetime menses, hormone replacement therapy linked to improvements in PH
SAN DIEGO — Measures of pulmonary vascular disease and right ventricular function improved with longer lifetime menses in pulmonary hypertension, according to research presented at the American Thoracic Society International Conference.
Two new devices for advanced pulmonary embolism thrombolysis show promise
Two catheter-directed thrombectomy devices demonstrated efficacy and safety in the treatment of acute intermediate-risk pulmonary embolism, speakers reported.
American Kidney Fund awards Clinical Science in Nephrology fellowships to researchers
The American Kidney Fund has chosen the recipients of this year’s Clinical Science in Nephrology fellowship program, which supports researchers working to improve the quality of care for patients with kidney disease.
Pulmonary arterial hypertension characteristics, mortality vary across US
Among adults with pulmonary arterial hypertension, patient characteristics, mortality and treatment varied across four U.S. census regions, according to results published in Annals of the American Thoracic Society.
FDA approves sotatercept for pulmonary arterial hypertension
The FDA has approved sotatercept, an activin signaling inhibitor, for treating adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.
FDA approves combination therapy tablet for pulmonary arterial hypertension
The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.
Benefit of upfront combination therapy not seen in low-risk PAH
Upfront combination therapy for patients with low-risk pulmonary arterial hypertension was not significantly better than monotherapy when assessing time to clinical worsening, according to results published in CHEST.